Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Joseph Keane(Trinity College), M. Miles Braun(Center for Biologics Evaluation and Research), Sharon K. Gershon(Center for Biologics Evaluation and Research), John Kasznica(Boston University), Robert P. Wise(Center for Biologics Evaluation and Research), Jeffrey Siegel(Center for Drug Evaluation and Research), William D. Schwieterman(United States Food and Drug Administration), Elizabeth Mirabile‐Levens(Pulmonary Associates)
Cited by 3,706
Related Papers
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
|Arthritis & Rheumatism|2003|387